Cissus quadrangularis for Health & Longevity

Evidence Review created on 09/27/2026 using AI4L + evidence-mcp / GPT 6

Also known as: Cissus, Veldt Grape, Hadjod, Asthisamharaka, Asthishrinkhala, Pirandai, Phet Sang Khat, Adamant Creeper, Winged Treebine, Devil’s Backbone, Single-Stemmed Wild Grape, Cissus quadrangulus, Saelanthus quadragonus, Vitis quadrangularis, CQR-300, CQ, Bone Setter, Asthisandhan, Asthisandhani, Hodjod, Harjor, Cissus bifida, Cissus edulis, Cissus fischeri, Cissus quadrangula, Cissus succulenta, Cissus tetragona, Cissus tetraptera, Cissus triandra, Vitis succulenta

Motivation

Cissus quadrangularis is a climbing plant whose stems and leaves are used in traditional medicine and modern oral supplements. It attracts interest from adults seeking to maintain comfortable movement, support recovery, and manage body weight as part of a longer, active life. Its place in health optimization raises questions about both meaningful outcomes and the consequences of repeated use.

Traditional use centers on bone and joint complaints, while modern research has also examined body measurements and blood markers. Products range from plant powders to concentrated extracts, sometimes combined with other ingredients. Human studies have investigated people recovering from fractures, adults with exercise-related joint symptoms, and people with excess body weight. Those settings differ from preventive use by an already active adult with favorable health measures.

This review examines the evidence for Cissus itself, the relevance of different preparations and study populations, potential adverse effects, and the practical meaning of published dosing and monitoring approaches. It separates outcomes that matter in daily life from laboratory findings and considers how each relates to health and longevity.

Benefits - Risks - Protocol - Conclusion

These sources introduce the traditional uses, clinical questions, and popular interpretations surrounding Cissus quadrangularis.

Four publicly verifiable sources were selected. Patrick’s accessible match was an audience question without a verifiable answer; no relevant discussion was found from Attia, Kresser, or Lifespan.io. Life Extension’s on-site search remained inaccessible; its relevant commentary was found through web search.

Grokipedia

Cissus quadrangularis

Provides botanical identity, distribution, traditional uses, and research context. This generated reference overview is background material; clinical claims are evaluated against the original studies below.

Examine

Cissus quadrangularis

Summarizes joint, bone, and weight research and formulation-dependent doses. The public overview discusses methodological limitations and commercial bias; detailed study tables include member-only content.

ConsumerLab

No dedicated ConsumerLab article for Cissus quadrangularis was found. Related results concern OsteoMD, African mango combinations, and manufacturing warnings; these are not dedicated reviews of Cissus alone.

Systematic Reviews

These systematic reviews (structured evidence assessments) and meta-analyses (analyses pooling study results) assess clinical effects and safety, prioritizing relevant, recent human datasets.

Safety is represented within these reviews, but no dedicated systematic review of long-term Cissus harms was identified. Combination-product effects cannot establish the contribution of Cissus itself.

Mechanism of Action

Cissus quadrangularis contains multiple plant chemicals rather than one defined active drug. Extracts contain flavonoids (plant compounds with biological activity), plant sterols, and other constituents whose proportions depend on the plant part and extraction process. Laboratory experiments suggest effects on bone-forming cells, inflammatory signaling, and digestive enzymes. In cell experiments, NF-κB (a regulator of inflammatory gene activity) was suppressed and heme oxygenase-1 (an enzyme involved in cellular stress protection) increased. These findings establish possible mechanisms, not clinical disease prevention. Bafna et al., Srisook et al.

Several explanations compete for reported weight changes: reduced appetite or food intake, altered carbohydrate and fat digestion, and changes in fat-cell behavior. Human-cell experiments suggesting increased heat-producing capacity do not show that orally administered extracts increase energy expenditure in people. A newer trial using extracts supplied by Gateway Health Alliances measured GLP-1 (a gut hormone involved in appetite and glucose regulation) and DPP-4 (an enzyme that breaks down that hormone), supporting another hypothesis without establishing drug-equivalent activity. Chatree et al., Youovop et al.

Human absorption, tissue distribution, active metabolites, elimination half-lives, and principal metabolizing enzymes remain inadequately characterized. There is no established receptor selectivity or reliable conversion between extract strengths. Circulating serotonin changes also cannot establish brain exposure or improved mood.

Historical Context & Evolution

Cissus quadrangularis has a long history in South Asian and African traditional medicine, particularly for fractures, pain, and digestive complaints. Names such as Hadjod and “bone setter” reflect that history. Traditional preparations include plant powders and extracts; this diversity matters because modern products do not necessarily reproduce the original preparation. Experimental bone-healing findings helped move the plant into supplements marketed for exercise recovery and health optimization. Bafna et al.

In the 2000s, research expanded to weight and metabolic outcomes. Early studies reported favorable changes with both single extracts and mixtures. The commercial connection is material: Gateway Health Alliances supplied proprietary CQR-300 in several influential trials, including the 2007 study, and later Nash et al. included commercial affiliations at PhytoQuest and Harinder Medicare. The university funded the latter study; supplier involvement and overlapping investigators still limit independent replication.

Subsequent evidence complicated the picture. A 2021 controlled trial did not reproduce weight or metabolic advantages, and a 2022 trial found no bone-density advantage. Newer positive metabolic research again used Gateway-supplied extracts. Interpretation therefore depends on formulation, controls, and outcome selection rather than a simple progression from traditional use to demonstrated longevity benefit.

Expected Benefits

Grades describe the evidence behind each outcome, with conflicting or indirect human findings classified as Low. None of the trials measured lifespan or years lived without disability.

High 🟩 🟩 🟩

No benefit reaches High: replicated positive clinical findings are undermined by conflicting controlled results, while many bone findings concern unvalidated blood markers.

Medium 🟩 🟩

Local bone formation during dental reconstruction

A randomized controlled trial (a study assigning participants by chance to treatment or comparison) in 20 adults undergoing surgical lengthening of jawbone found greater local bone density and maturation with Cissus. This procedural outcome may support dental reconstruction, but does not establish systemic bone strengthening or prevention of fractures in otherwise healthy adults. Altaweel et al.

Magnitude: At six months after implantation, mean local bone density was 774.6 versus 671.3 Hounsfield units (an imaging measure of tissue density) with Cissus versus control; the small procedural study does not establish fracture prevention.

Low 🟩

Weight and body-fat reduction ⚠️ Conflicted

Trials report losses with proprietary extracts, including a 16-week study, whereas the Thai trial found no benefit over placebo for weight, fat, or waist. Extract differences, dietary measurement, and commercial involvement may contribute. Net reading: a possible formulation-specific effect remains uncertain. Nash et al., Chatree et al., Youovop et al.

Magnitude: The newer Cissus arm reported 5.8% weight reduction over 16 weeks; this is a within-group change (from treated participants’ own baseline), not a placebo-adjusted effect (change exceeding the comparison group’s change). The Thai trial showed essentially unchanged weight after eight weeks.

Blood-lipid improvement ⚠️ Conflicted

Positive single-extract trials reported improved cholesterol and triglycerides, but the Thai trial found no treatment effect. Much pooled evidence combines Cissus with other ingredients. Net reading: lipid changes are inconsistent and have not been linked to fewer cardiovascular events. Oben et al., Chatree et al.

Magnitude: One six-week CQR-300 arm with dietary restriction reported 29.0% lower LDL cholesterol (cholesterol carried by low-density lipoproteins) and 21.7% lower triglycerides from baseline; another controlled trial did not reproduce a treatment effect.

Glucose regulation ⚠️ Conflicted

Some trials reported lower fasting glucose with Cissus, including a recent appetite-hormone study. The Thai trial found no treatment effect on glucose or insulin-related measures. Net reading: glucose improvement remains inconsistent, with no demonstrated prevention of diabetes. Oben et al., Chatree et al., Youovop et al.

Magnitude: A diet-restricted CQR-300 arm reported a 14.6% fasting-glucose reduction from baseline over six weeks; the independent eight-week trial found no treatment effect.

Blood-pressure reduction ⚠️ Conflicted

A small CQR-300 trial reported lower blood pressure than placebo, while the Thai study found no treatment effect. Participants and extracts differed, and prevention of cardiovascular events was not tested. Net reading: a blood-pressure benefit remains uncertain. Nash et al., Chatree et al.

Magnitude: In the eight-week pilot, systolic pressure fell from 133.2 to 121.6 mmHg with CQR-300 and from 127.6 to 126.2 mmHg with placebo. The separate Thai trial found no treatment effect.

Joint pain and function

An uncontrolled study in 29 trained men reported better joint symptoms after eight weeks. A small osteoarthritis (degenerative joint disease) study lacked an inert-placebo group. Expectation and symptom fluctuation remain alternatives; tendon repair and cartilage regeneration were not demonstrated. Bloomer et al., Viswanath et al.

Magnitude: Mean WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index, a pain and function questionnaire) total score fell from 25.4 to 17.4, approximately 31%, in the uncontrolled exercise study.

Fracture recovery and associated pain ⚠️ Conflicted

Small studies and a systematic review suggest less bone pain or faster recovery after fractures. A randomized jaw-fracture pilot found no significant clinical or imaging improvement despite a blood-marker change. Net reading: fracture recovery findings are mixed and cannot establish preventive bone benefits. Sawangjit et al., Jaw-fracture pilot

Magnitude: In a nine-person pilot, pain and swelling were absent by day 15 in the five Cissus-treated participants. The later randomized jaw-fracture pilot found no clinical or imaging advantage; the small studies do not establish a reliable recovery-time reduction. Brahmkshatriya et al.

Speculative 🟨

Longer healthy lifespan

No human lifespan or disability-free survival outcome was identified. The rationale extrapolates from metabolic and inflammatory mechanisms; antioxidant assays and bone-turnover changes cannot establish a longevity effect. Bafna et al.

Mood, sleep, and stress resilience

Claims rely on circulating serotonin changes and mechanistic interpretation, rather than controlled improvements in mood, sleep, or stress. Blood serotonin is not a measure of brain serotonin. Oben et al.

Muscle growth and connective-tissue repair

Traditional use and experimental tissue effects motivate these claims. Controlled human evidence does not establish muscle growth, tendon healing, or ligament repair; an increase in creatinine cannot demonstrate added muscle. Stohs & Ray

Claims without demonstrated clinical benefit: In 134 randomized postmenopausal women with osteopenia (bone density below normal but above the osteoporosis threshold), 24 weeks of Cissus did not improve bone density versus placebo. Hemorrhoids (swollen blood vessels around the anus) improved similarly with Cissus and placebo in a 570-person trial. Neither establishes a useful benefit. Benjawan et al., Panpimanmas et al.

Benefit-Modifying Factors

  • Formulation: Powder, water extracts, other solvent extracts, and multi-ingredient products are not interchangeable. CQR-300 metabolic results cannot be transferred by matching milligrams alone.
  • Baseline markers: Weight studies mainly enrolled adults with overweight or obesity. Benefits at already favorable glucose, lipid, blood-pressure, or body-fat levels have not been established.
  • Sex: Joint-symptom evidence in trained adults comes from men. The bone-density trial studied postmenopausal women; neither provides a validated sex-specific response rule.
  • Existing conditions: Recovery after a fracture or dental procedure differs from preventing fractures. Diabetes, advanced illness, and concurrent medication use were commonly excluded from metabolic trials.
  • Age: Evidence is sparse for adults older than 65 and for frailty. Weight reduction without preservation of strength or muscle would not meet a longevity-oriented functional goal.
  • Genetics: No validated genetic predictor of benefit or genotype-guided dose was identified.

Potential Risks & Side Effects

Short trials generally reported few serious problems; that does not quantify rare events or safety during years of use. The 2017 systematic review found no reported serious adverse effects, while the 24-week bone trial found similar adverse-event incidence across groups.

High 🟥 🟥 🟥

No harm reaches High: trials do not establish a replicated excess of a specific adverse event attributable to Cissus alone.

Medium 🟥 🟥

No harm reaches Medium: available symptoms are incompletely attributed, reported in mixed formulations, or inconsistent with placebo comparisons.

Low 🟥

Digestive and oral discomfort

Trials reported gas, nausea, constipation, diarrhea, dry mouth, and an isolated mouth ulcer. Some symptoms also occurred with placebo; small samples and mixed preparations prevent confident causal attribution or reliable population-risk estimates. Chatree et al., Oben et al., pharmacist-reviewed monograph

Magnitude: In the Thai trial, 3/15 Cissus recipients reported constipation and 3/15 dry mouth, versus 1/15 and 2/15 placebo recipients. Diarrhea, gas, nausea, and mouth ulcer each occurred in 1/15 Cissus recipients; nausea also occurred in 1/15 controls. These observed counts do not establish attributable risk.

Headache, dizziness, and sleep disturbance

Headache and difficulty sleeping occurred in a trial including Cissus-only, combination, and placebo arms. The Thai trial also reported dizziness in both groups. Causal attribution remains uncertain, but these symptoms can interfere with training, recovery, and adherence. Oben et al., Chatree et al.

Magnitude: Four headache and four lack-of-sleep reports occurred across 72 participants without treatment-specific excess counts. In the Thai trial, dizziness occurred in 1/15 participants in each group; headache occurred in 1/15 Cissus recipients.

Warm sensations

The Thai trial reported warmth more often with Cissus than placebo. Its small sample and symptom reporting without a demonstrated causal excess make this an uncertain tolerability signal; the mechanism is unknown. Chatree et al.

Magnitude: Warm sensations occurred in 4/15 Cissus recipients and 1/15 placebo recipients over eight weeks; these small counts do not establish a dependable population-risk estimate.

Low platelet count

One elderly kidney-transplant recipient developed thrombocytopenia (a low blood-platelet count) while using Cissus with azathioprine and prednisolone. Platelets normalized after Cissus withdrawal; concomitant illness and drugs limit attribution. Bleeding risk makes the signal important despite the isolated report. Kulkarni & Bhat

Magnitude: Not quantified in available studies. Only one case report exists, so the frequency and risk attributable to Cissus cannot be estimated.

Uncertain kidney-marker changes ⚠️ Conflicted

An older trial reported higher creatinine, a blood marker influenced by kidney filtration and muscle metabolism. Another trial found no kidney-test changes, and neither demonstrated kidney injury. Net reading: the laboratory signal warrants contextual interpretation, not a claim of kidney toxicity or muscle gain. Oben et al., Chatree et al.

Magnitude: Creatinine increased 23.5% from baseline in the older CQR-300 arm; a separate eight-week trial showed no treatment effect on kidney measures.

Speculative 🟨

Excess glucose lowering

Additive hypoglycemia (abnormally low blood glucose) is theoretically possible with glucose-lowering treatment. Clinical interaction trials are absent; safety references extrapolate from some glucose-lowering findings. Pharmacist-reviewed monograph

Hormonal or reproductive effects

An isolated plant fraction showed estrogen-like activity in female rats. Effects on human hormone-sensitive conditions, pregnancy, and fetal development remain unknown; ordinary commercial extracts may differ substantially. Aswar et al.

Sedation and impaired coordination

High-dose animal observations suggest sedative or muscle-relaxing effects. Human impairment and dose thresholds have not been established, including around exercise or with sedating substances. Examine overview

Risk-Modifying Factors

  • Baseline markers: Low glucose or an abnormal platelet count could amplify consequences of glucose lowering or a recurrent platelet reaction. Existing kidney-test abnormalities complicate interpretation of creatinine changes.
  • Existing disease: Transplant status, blood disorders, significant kidney or liver disease, and multiple medications increase uncertainty because these groups were poorly studied.
  • Sex and reproduction: No reliable sex difference in adverse-event rates is established. Pregnancy and breastfeeding lack adequate human safety evidence; animal estrogen-like activity cannot quantify human risk.
  • Age: Older adults face greater consequences from impaired coordination, low glucose, and medication interactions; age-specific dosing and long-term safety are unestablished.
  • Genetics: No clinically validated genetic risk marker or pharmacogenetic test exists for Cissus use.
  • Product composition: Caffeine or other added botanicals can independently cause symptoms and interactions. Extract concentration and contaminants may matter more than the stated amount of whole-plant equivalent.

Key Interactions & Contraindications

Interactions are mostly theoretical; the pharmacist-reviewed monograph identifies potential additive glucose lowering rather than established clinical interaction rates.

  • Glucose-lowering drugs — caution/monitor: Insulin and sulfonylureas (insulin-releasing drugs; glipizide, glimepiride) could increase low-glucose risk; metformin, semaglutide, and sitagliptin combinations remain untested. Early glucose checks address uncertainty; no validated spacing rule prevents it.
  • Transplant medication — caution: The platelet case involved azathioprine and prednisolone. A direct interaction is unproven, but possible overlapping blood toxicity makes unsupervised co-use difficult to evaluate; platelet monitoring does not establish safety.
  • Bleeding-related medicines — caution: Anticoagulants (clot-preventing drugs; warfarin, apixaban) and nonprescription aspirin or ibuprofen could worsen bleeding if platelets fall. This precaution does not establish direct clotting inhibition by Cissus. Unexplained bruising or bleeding triggers discontinuation and assessment.
  • Sedating substances — caution: Benzodiazepines (sedative drugs; diazepam), nonprescription diphenhydramine, alcohol, and valerian could theoretically compound animal-observed sedation. Human interaction data and a protective dose separation are unavailable.
  • Glucose-lowering supplements — caution/monitor: Berberine, bitter melon, and chromium may add glucose-lowering effects. Fasting, calorie restriction, and prolonged exercise could further increase susceptibility; glucose checks are especially relevant when medications also lower glucose.
  • Serotonin-related agents — caution: Antidepressants (medicines for depression; sertraline, fluoxetine), tramadol, and 5-hydroxytryptophan raise theoretical concern from serotonin findings. No Cissus-induced serotonin syndrome (dangerous excessive serotonin activity) was identified. Blood serotonin alone cannot establish an interaction.
  • Surgery — precaution: Potential glucose changes and uncertain drug interactions complicate perioperative assessment. A two-week interruption is a conservative herbal-product convention, not a Cissus half-life-derived washout or an experimentally validated interval.

Populations who should avoid Cissus quadrangularis:

  • Individuals with a prior allergic reaction or suspected Cissus-associated platelet decline.
  • Pregnant or breastfeeding individuals and children, because safety for elective supplementation is unestablished.
  • Organ-transplant recipients using immunosuppression, particularly with unexplained low platelets; the published case supports a precaution, not a quantified contraindication threshold.
  • Individuals with active bleeding or unexplained thrombocytopenia; no Cissus-specific safe platelet cutoff is established.

Severe kidney or liver disease has no validated dose-adjustment or safety threshold. No formal prescription contraindication framework exists for this botanical.

Risk Mitigation Strategies

  • Product isolation: A single-ingredient, traceable extract makes digestive symptoms, insomnia, and other adverse events easier to attribute; recording the batch and dose avoids confusion from changing formulations.
  • Early symptom review: A tolerability check within one to two weeks can identify headache, digestive symptoms, or sleep disruption. Persistent symptoms provide a practical discontinuation criterion rather than a reason to escalate dosing.
  • Platelet safety: New unexplained bruising, pinpoint skin bleeding, or persistent bleeding warrants cessation and prompt evaluation, mitigating possible consequences of the reported platelet reaction.
  • Glucose safety: With glucose-lowering medication, baseline and early-treatment glucose measurements address possible additive effects. A value below 70 mg/dL or symptomatic low glucose is an assessment trigger, not an efficacy target.
  • Kidney-marker interpretation: Comparing creatinine with baseline, hydration, exercise, and medications reduces misinterpretation of laboratory changes. An unexplained rise is not evidence of muscle growth.
  • Training safety: Avoiding escalation of training loads solely because pain improves reduces the risk of masking an unresolved injury. Sleep disruption or sedation can independently impair recovery and coordination.

Therapeutic Protocol

  • Evidence boundary: No validated longevity regimen or standard protocol used by leading practitioners was identified. Published regimens address specific outcomes; none establishes lifelong preventive dosing.
  • Metabolic studies: CQR-300 was studied at 300 mg/day, either once before breakfast or as 150 mg twice daily before meals, for six to sixteen weeks. These are extract-specific research regimens. Nash et al., Oben et al.
  • Alternative metabolic regimen: A different extract at 300 mg after breakfast and dinner for eight weeks did not establish a weight or metabolic advantage over placebo. Higher total extract mass did not imply greater benefit. Chatree et al.
  • Joint-symptom study: Bloomer and colleagues used 3,200 mg/day orally for eight weeks in trained men. This uncontrolled regimen cannot define an optimal dose, validated escalation schedule, or treatment for tendon injury. Pilot study
  • Bone studies: Dental reconstruction used 500 mg/day for six weeks. The postmenopausal trial studied 1.2 or 1.6 g/day for 24 weeks without a bone-density advantage. These approaches address different settings. Dental trial, Bone-density trial
  • Timing and half-life: No superior time of day, human elimination half-life, or evidence-based washout is known. Once-daily and divided regimens reflect study design; meal timing is not interchangeable evidence of absorption.
  • Dose modifiers: No validated genetic, sex-specific, or age-adjusted dose exists. Older adults, pregnancy, and significant kidney or liver impairment are not supported by adequate dosing studies.
  • Baseline and goals: Existing weight excess, elevated glucose or lipids, joint symptoms, and recent procedures define the studied contexts. Favorable baseline markers offer no established preventive rationale for increasing the dose.

Discontinuation & Cycling

  • Duration: Most metabolic or joint studies lasted six to sixteen weeks; the bone-density study lasted 24 weeks. Evidence does not establish lifelong supplementation or persistence of benefits after cessation.
  • Withdrawal: No defined dependence or withdrawal syndrome has been demonstrated. Return of symptoms or weight after discontinuation has not been adequately studied.
  • Tapering: No evidence-based taper is established; trials do not suggest a pharmacological need for gradual reduction. Suspected adverse reactions require evaluation rather than an automatic taper.
  • Cycling: No controlled evidence shows that cycling maintains efficacy or prevents harms. Serotonin-based cycling claims do not establish an effective schedule.

Sourcing and Quality

  • Identity: A useful specification names Cissus quadrangularis, the plant part, extraction solvent, amount per serving, and batch. Powders and extracts with the same milligram label can deliver different constituents.
  • Studied ingredient: CQR-300 is a named research extract supplied by Gateway Health Alliances; its presence is a formulation identifier, not independent proof of efficacy or certification of every retail product. Trial preparation
  • Independent testing: Batch-specific laboratory documentation for botanical identity, heavy metals, pesticides, microbes, and residual solvents addresses contamination and misidentification. Independent verification is more informative than an unsupported purity claim.
  • Standardization: “Ketosteroids,” “phytosterols,” and whole-plant equivalents are not interchangeable potency measures. No validated constituent concentration predicts clinical response; a high percentage alone does not demonstrate greater benefit. Narrative assessment
  • Combination products: Products containing other botanicals, vitamins, or caffeine represent different interventions. No current retail brand is endorsed here because independent batch quality and equivalence to studied preparations were not verified.
  • Contaminants: A laboratory survey that included Cissus products detected variable metal content across herbal supplements. It establishes a quality-control issue, not clinical poisoning attributable to every Cissus product. Barrella et al.

Practical Considerations

  • Time to assessment: Published symptom and metabolic assessments generally span four to sixteen weeks. Immediate perceived effects do not establish tissue healing, and six-month bone-marker changes did not establish increased bone density.
  • Common interpretation errors: Improvement from baseline is not necessarily improvement over placebo. Pooling mixture studies, interpreting creatinine as muscle gain, or interpreting pain relief as tendon repair can exaggerate benefit.
  • Regulatory status: In the United States, supplements are not preapproved for effectiveness or safety in the manner of medicines. Marketing a Cissus supplement does not establish approval for fracture healing, obesity, or longevity. FDA consumer information
  • Access and burden: Oral capsules are practically accessible, but research-equivalent formulations and independent batch documentation may be harder to obtain. Repeated tracking and laboratory assessment can exceed the burden of administration itself.

Interaction with Foundational Habits

  • Sleep: Possible direct adverse interaction: insomnia is reported but not causally established. No controlled sleep benefit exists. Recording sleep timing and quality can distinguish a symptom signal from changes in caffeine, stress, or training.
  • Nutrition: Possible direct interaction through appetite or glucose regulation; clinical results conflict. Stable food intake improves interpretability, while preserving adequate protein and overall nutrition matters if weight falls. No study establishes that Cissus compensates for poor diet or requires a specific dietary pattern.
  • Exercise: A possible indirect benefit is better training tolerance through reduced joint symptoms, based on uncontrolled evidence. No established enhancement or blunting of muscle adaptation exists. Maintaining stable training and distinguishing pain from tissue healing are central practical considerations.
  • Stress management: No established direct interaction or controlled evidence of better stress resilience exists. Circulating serotonin is an insufficient mechanism for inferring psychological benefit; changes in stress-management practices can confound perceived mood or sleep effects.

Monitoring Protocol & Defining Success

Baseline assessment in the studies included body measurements and selected blood tests. A structured evaluation can document the intended outcome, dose, formulation, medications, sleep, and training before exposure. Weight, waist, joint symptoms, glucose, and lipids are relevant only to the goal being examined. Blood count and kidney or liver tests are context-dependent safety assessments, not a validated mandatory Cissus panel.

An illustrative observation schedule is baseline, tolerability review at one to two weeks, and outcome review at eight to twelve weeks. Where laboratory follow-up is justified, repeating the relevant baseline tests at eight to twelve weeks enables comparison; symptoms or abnormal results warrant earlier assessment. No Cissus-specific functional-medicine optimal ranges have been validated. Success means a reproducible, goal-relevant change without impaired sleep, strength, nutrition, or safety, rather than an isolated favorable biomarker.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Weight and waist No established Cissus target; track change from personal baseline Evaluate body composition goal Same scale, waist landmark, and time; weekly averages reduce daily noise. Preserve strength and nutrition.
Fasting glucose 80–86 mg/dL is the cited integrative-practitioner target; no Cissus-specific optimum is established Assess glucose response and safety Diabetes and Glucose Control, from supplement retailer Life Extension, proposes this narrower target; conventional normal fasting glucose is below 100 mg/dL. The proposed range is not a validated Cissus endpoint. Compare consistent overnight fasts; below 70 mg/dL is a safety trigger.
Lipid profile No established Cissus-specific functional range; track baseline and the existing individualized prevention target Assess claimed lipid benefit Similar fasting conditions when comparing triglycerides. Trial changes do not establish fewer cardiovascular events.
Blood pressure No established Cissus-specific optimal range; track personal baseline and the existing individual target Assess claimed pressure benefit Compare seated readings after rest, with a consistent cuff and repeated measurements; low readings with dizziness are adverse outcomes.
Platelet count No established Cissus optimum; track baseline and unexplained falls Investigate bleeding signal CBC (complete blood count, a test including platelets) assesses platelet levels. Typical laboratory platelet range is approximately 150–450 × 10⁹/L; symptoms and trends matter.
Creatinine and kidney filtration estimate No established Cissus target; track personal baseline Assess unexplained kidney-marker changes Hydration, strenuous exercise, and muscle mass affect interpretation. An unexplained rise is a safety question, not a desired response.
Liver enzymes and bilirubin No established Cissus-specific optimum; track baseline and laboratory range Contextual safety assessment Most relevant with liver disease, symptoms, or concurrent products; routine serial testing in healthy users is not validated.
Bone density No established Cissus target; track clinically indicated change beyond measurement error Assess established bone-health concerns DXA (dual-energy X-ray absorptiometry, an X-ray bone-density measurement) assesses bone density. Short-interval repeat scans and blood bone markers cannot prove fracture protection.
  • Joint function: A consistent pain score and a predefined activity record are more interpretable than vague impressions of recovery.
  • Sleep and tolerability: Track sleep disruption, headache, digestive discomfort, bruising, and dizziness alongside dose changes.
  • Functional success: Stable or improved strength, activity, and nutrition matter more than weight loss alone for health-oriented adults.

Emerging Research

  • Registered metabolic study: NCT06827002 lists 248 participants and appetite-hormone outcomes, with Cissus and Dichrostachys glomerata in separate arms. The registry remains active, not recruiting; a related Youovop et al. publication already reports results. These are not independent replications.
  • Reporting questions: The Youovop paper has inconsistent three-versus-four-group statistical descriptions and reports discomfort-related withdrawals alongside a statement that adverse events required no discontinuation. Registration followed enrollment. These issues weaken precision and do not establish equivalence to semaglutide. Primary report
  • Combination trial: NCT07363148 plans 120 adults receiving MB-1 or placebo for 84-day weight outcomes. Arrae, a commercial sponsor, lists the trial as not yet recruiting with no results. MB-1 contains Cissus plus several other ingredients; any result will concern the mixture.
  • Bone outcomes: Na Takuathung et al., 2025 found very uncertain marker evidence. Larger trials measuring fracture recovery, function, and fracture incidence could either substantiate traditional claims or show that blood-marker changes lack practical benefit.
  • Independent metabolic replication: The conflict between Nash et al., 2019 and Chatree et al., 2021 makes standardized extracts, measured food intake, maintained exercise, and longer follow-up particularly informative. Results in already active, metabolically healthy adults could differ in either direction.
  • Long-term safety and longevity: Rare-event surveillance and repeated-dose studies could identify harms missed by small trials or strengthen reassurance. No human trial with lifespan or disability-free survival as an outcome was identified in the PubMed and ClinicalTrials.gov searches through September 27, 2026.

Conclusion

Cissus quadrangularis is a traditional medicinal plant now used in supplements for bones, joints, and weight control. Its relevance to longevity is indirect: preserving comfortable movement, recovering from injury, and improving blood sugar or cholesterol could matter to active adults, but these possibilities do not establish longer life or more years in good health.

The clearest positive signals concern particular settings and preparations. A small dental reconstruction trial found better local bone formation, and an exercise study without a comparison group reported less joint discomfort. Weight, blood sugar, and cholesterol findings conflict across controlled studies. Bone-density and hemorrhoid trials did not demonstrate useful advantages over placebo. Much of the favorable weight-management research involves branded extracts supplied by Gateway Health Alliances, overlapping researchers, or ties to businesses, limiting confidence in independent confirmation. Life Extension commentary also comes from a supplement retailer.

Short studies generally reported few serious problems. Digestive symptoms, headache, and disturbed sleep occurred, although their connection to Cissus remains uncertain. An isolated reversible decline in blood platelets and unexplained changes in kidney blood tests add uncertainty. Extract identity, other ingredients, and concurrent medication use affect interpretation.

For health-oriented adults already investing in exercise, nutrition, sleep, and careful tracking, possible symptom and weight-control benefits remain uncertain and dependent on the preparation. The evidence does not establish reliable tissue repair, preventive bone strengthening, or longer healthy life.

Top - Benefits - Risks - Protocol